ATE419267T1 - Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten - Google Patents

Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Info

Publication number
ATE419267T1
ATE419267T1 AT04761607T AT04761607T ATE419267T1 AT E419267 T1 ATE419267 T1 AT E419267T1 AT 04761607 T AT04761607 T AT 04761607T AT 04761607 T AT04761607 T AT 04761607T AT E419267 T1 ATE419267 T1 AT E419267T1
Authority
AT
Austria
Prior art keywords
surrogates
peptide binding
containing peptide
macrocycles containing
spacially
Prior art date
Application number
AT04761607T
Other languages
German (de)
English (en)
Inventor
Pierre Deslongchamps
Yves Dory
Luc Ouellet
Gerald Villeneuve
Mahesh Ramaseshan
Daniel Fortin
Mark Peterson
Hamid Hoveyda
Sylvie Beaubien
Eric Marsault
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Application granted granted Critical
Publication of ATE419267T1 publication Critical patent/ATE419267T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04761607T 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten ATE419267T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49125003P 2003-07-31 2003-07-31
US49125303P 2003-07-31 2003-07-31
US49124903P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
ATE419267T1 true ATE419267T1 (de) 2009-01-15

Family

ID=34119808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761607T ATE419267T1 (de) 2003-07-31 2004-08-02 Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten

Country Status (7)

Country Link
US (2) US7550431B2 (fr)
EP (1) EP1648923B1 (fr)
JP (1) JP4928263B2 (fr)
AT (1) ATE419267T1 (fr)
CA (1) CA2533820C (fr)
DE (1) DE602004018782D1 (fr)
WO (1) WO2005012332A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
WO2004111077A1 (fr) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Antagonistes macrocycliques du recepteur de motiline
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP2319859B1 (fr) * 2003-07-31 2013-03-27 Tranzyme Pharma Inc. Composés macrocycliques définis spatialement utiles pour la découverte de médicaments
WO2006046977A1 (fr) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Antagonistes macrocycliques du recepteur de la ghreline et procedes d'utilisation
JP5122446B2 (ja) * 2005-06-13 2013-01-16 トランザイム・ファーマ,インコーポレイテッド 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
EP2431380A3 (fr) 2006-09-11 2013-07-03 Tranzyme Pharma, Inc. Antagoniste macrocyclique du récepteur de motiline pour le traitement des troubles de dysmotilité gastro-intestinale
KR20090107088A (ko) * 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
WO2010009334A1 (fr) * 2008-07-17 2010-01-21 Colorado State University Research Foundation Procédé de préparation d’analogues de largazole et ses utilisations
EP2350031A2 (fr) * 2008-08-20 2011-08-03 Ensemble Therapeutics Corporation Composés destinés à l inhibition du facteur de nécrose tumorale alpha
MX2011008857A (es) 2009-02-27 2011-09-30 Raqualia Pharma Inc Derivados de oxiindol con actividad agonistica del receptor de motilina.
EP2493910A1 (fr) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2978730A1 (fr) 2015-03-06 2016-09-15 Colorado State University Research Foundation Synthese et utilisation de nouveaux analogues de largazole
WO2016144665A1 (fr) 2015-03-06 2016-09-15 Colorado State University Research Foundation Procédé de préparation de particules creuses et leurs utilisations
WO2017049383A1 (fr) 2015-09-24 2017-03-30 Cyclenium Pharma Inc. Bibliothèques de composés macrocycliques contenant hétéroaryle et procédés pour leur fabrication et leur utilisation
CN108350028B (zh) 2015-10-27 2021-12-07 豪夫迈·罗氏有限公司 对抗鲍曼不动杆菌(Acinetobacter baumannii)的肽大环
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
US20190153620A1 (en) * 2016-05-16 2019-05-23 Cyclenium Pharma Inc. Libraries of diverse macrocyclic compounds and methods of making and using the same
WO2017222935A1 (fr) * 2016-06-20 2017-12-28 Kansas State University Research Foundation Inhibiteurs thérapeutiques à petites molécules contre les picornavirus, calicivirus, et coronavirus
EP3388444A1 (fr) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Macrocycles peptidiques antibactériens et utilisation associée
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
EP0804460A1 (fr) * 1995-01-20 1997-11-05 Molecumetics, Ltd. Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
JP2002506423A (ja) * 1997-04-11 2002-02-26 イーライ・リリー・アンド・カンパニー ペプチド模倣型大員環のコンビナトリアルライブラリーとそのための方法
US20020068301A1 (en) 1997-05-28 2002-06-06 Hung-Sen Lai Cyclic peptide libraries and methods of use thereof to identify binding motifs
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
CA2284459C (fr) * 1999-10-04 2012-12-11 Neokimia Inc. Synthese combinatoire de bibliotheques de composes macrocycliques utiles pour la decouverte de medicaments
EP1222197A4 (fr) 1999-10-04 2004-07-21 Merck & Co Inc Proteine mray et gene de pseudomonas aeruginosa
AU2001283938A1 (en) * 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
EP1312612A4 (fr) 2000-08-24 2004-09-22 Chugai Pharmaceutical Co Ltd Derive de peptide cyclique
IL141276A0 (en) 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
WO2004111077A1 (fr) * 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Antagonistes macrocycliques du recepteur de motiline
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP2319859B1 (fr) * 2003-07-31 2013-03-27 Tranzyme Pharma Inc. Composés macrocycliques définis spatialement utiles pour la découverte de médicaments
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same

Also Published As

Publication number Publication date
JP2007526895A (ja) 2007-09-20
US8557765B2 (en) 2013-10-15
WO2005012332A1 (fr) 2005-02-10
CA2533820A1 (fr) 2005-02-10
DE602004018782D1 (de) 2009-02-12
US20050119169A1 (en) 2005-06-02
EP1648923B1 (fr) 2008-12-31
CA2533820C (fr) 2016-12-13
EP1648923A1 (fr) 2006-04-26
US7550431B2 (en) 2009-06-23
EP1648923A4 (fr) 2006-08-23
US20090312540A1 (en) 2009-12-17
JP4928263B2 (ja) 2012-05-09

Similar Documents

Publication Publication Date Title
ATE419267T1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
CY1111901T1 (el) Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
SG145725A1 (en) Anti-vegf antibodies
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
TW200611910A (en) Interferon-alpha polypeptides and conjugates
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
EP1617802A4 (fr) Polynucleotides specifiques de cngh0010, polypeptides, anticorps, compositions, methodes et utilisations
WO2006029220A3 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
MX2007011411A (es) Interaccion rage/diaphanous y composiciones relacionadas y metodos.
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2008036337A8 (fr) Réactifs permettant de détecter une phosphorylation de protéines dans les voies de signalisation de la leucémie
WO2004037997A3 (fr) Fragments et activite de la proteine rel chez m tuberculosis et autres utilisations de celle-ci
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
GB0312642D0 (en) Pharmaceutical composition
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
WO2004111180A3 (fr) Procedes et compositions pour enrichir selectivement des microbes
ATE430206T1 (de) Mss4 als antifungisches zielmolekül
WO2006008266A3 (fr) Proteines de liaison au facteur xi
DE60319582D1 (de) Cgt1 als antifungales target
WO2006002257A3 (fr) Kits de compositions de molecules relatives a pecam-1d de parties et procedes d'utilisation associes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties